18:26 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Bone stops Phase III of Preob cells in osteonecrosis for futility

Bone Therapeutics S.A. (Euronext:BOTHE) discontinued a Phase III trial of its Preob cells to treat osteonecrosis of the hip after an interim 12-month analysis by a DSMB showed that the trial was unlikely to meet...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

Bone-forming cells: Additional Phase IIa data

Additional data from 7 patients ages 40-85 who did not respond to anti-osteoporotic therapy in an investigator-led, open-label, Belgian Phase IIa trial showed that a single infusion of IV Preob led to a >=40% reduction...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Bone-forming cells: Phase IIa data

Data from 7 patients ages 40-85 who did not respond to anti-osteoporotic therapy in the first part of an investigator-led, open-label, Belgian Phase IIa trial showed that a single infusion of IV Preob led to...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Preob bone-forming cells: Phase IIb/III started

Bone Therapeutics began an open-label, European Phase IIb/III trial to compare a single administration of Preob vs. bone autograft in 176 patients with hypotrophic non-union fractures of long bones. Bone Therapeutics has rights to the...
07:00 , May 6, 2013 |  BC Week In Review  |  Clinical News

Preob bone-forming cells: Phase IIa started

Bone Therapeutics said researchers at the Erasme University Hospital began an open-label Phase IIa trial to evaluate a single dose of IV Preob in 20 patients with severe osteoporosis who did not respond to anti-osteoporotic...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

Preob bone-forming cells: Phase III started

Bone Therapeutics began a double-blind, placebo-controlled, European Phase III trial to evaluate Preob administered percutaneously via a minimally invasive approach in about 130 patients. The product has Orphan Drug designation in Europe and the U.S....